Platelet-derived growth factor subunit B (PDGFB) heparan sulfate binding site (PDGFB-HSBS)

The Platelet-derived growth factor B (PDGFB) heparan sulfate binding site, also known as the C-terminal retention motif, is a cluster of basic amino acids located at the C-terminus of the PDGFB protein (UniProt P01127). This site mediates the high-affinity interaction between PDGFB and heparan sulfate proteoglycans (HSPGs) within the extracellular matrix (ECM) and on cell surfaces (PubMed: 17210731). This anchoring is physiologically vital for the creation of localized growth factor gradients, which are necessary for the precise recruitment of pericytes to developing blood vessels and the maintenance of the blood-brain barrier (PubMed: 12670922). In diseases such as cancer, the loss of this retention motif or its competitive inhibition can lead to poorly organized vasculature and increased metastasis, while its overactivity is linked to various fibrotic disorders (PubMed: 17210731). Therapeutic interventions include the use of heparin mimetics to enhance wound healing or antagonists to disrupt pathological PDGFB signaling in tumors and fibrosis. For example, becaplermin is a recombinant form of PDGFB that utilizes this site to promote localized wound healing in diabetic ulcers (FDA Label). Conversely, inhibitors of the PDGF pathway, such as imatinib, are used to treat cancers driven by aberrant PDGFB activity, although they typically target the receptor rather than the binding site itself (PubMed: 12467226).

Other names

PDGF-B retention motifPDGF-B C-terminal basic sequencePDGF-B heparin-binding domainPDGF2SISSSVPlatelet-derived growth factor subunit B retention motif

The mechanism of action involves the modulation of PDGFB bioavailability and spatial distribution. Drugs like becaplermin provide exogenous PDGFB that anchors to the wound site via this binding site to promote healing (FDA Label). Conversely, heparin mimetics or antagonists can either stabilize the growth factor to enhance its activity or competitively block the site to prevent its sequestration in the extracellular matrix, thereby altering its ability to form the gradients necessary for pericyte recruitment and receptor activation (PubMed: 17210731, 12670922).